Products are color coded by category
Brain & sleep · Compound guide
Explore the mechanisms, study findings and evidence limits behind this research topic.
Product artwork identifies the SRP listing. It does not demonstrate safety or clinical benefit. The evidence guide and its sources follow below.
View product label and documentation →
Selank (also Selanc / TP-7) is a synthetic heptapeptide tuftsin analog with opened sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro / TKPRPGP (PubChem CID 11765600; CAS 129954-34-3; UNII TS9JR8EP1G; formula C33H57N11O9; MW 751.9 g/mol). It is not tuftsin (TKPR tetrapeptide), not Semax (MEHFPGP ACTH analog), and not an FDA-approved drug. Opened human reports are geographically concentrated and small. Human efficacy of a research-market 10 mg vial is not established. Historical papers that used the word “anxiolytic” are opened literature, not a treatment claim. Research use only. Not medical advice. Not for human use.
Educational information only. This page describes an investigational laboratory research heptapeptide. It is not medical advice. Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application. No human dosing, reconstitution, or administration protocol appears on this page. Historical Russian-language clinical papers that used the word “anxiolytic” are opened literature, not a treatment claim and not an FDA indication.
SRP product and index pages do not print CAS, UNII, PubChem CID, molecular formula, sequence, termini (free acid vs amide), salt form, or a public COA. Identity below is taken only from opened public registries and from primary papers that name Selank / Selanc / TP-7 / Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Opened SRP 10 mg product page (16 August 2026): title “Selank 10 mg Neuroscience Research Peptide Vial”. Category: Brain & Mind Research. Price printed $25.00. Subhead: Selank (10 mg Vial) — COA verified research compound. For laboratory research use only. Not for human consumption. Also known as: TP-7. Bullets: 10 mg lyophilized research compound per vial; COA available for batch verification; high-purity research material; intended for qualified laboratory and analytical research; securely packaged; Made and tested in the USA; For Research Use Only. Not for human or veterinary use. Description: supplied for controlled laboratory evaluation of Selank within Brain & Mind Research studies. Footer: for laboratory research only; not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application. Availability: 9 in stock (can be backordered). Product URL: http://simpleresearchpeptides.com/product/selank-10-mg-vial/.
Not printed on the opened product page and therefore not claimed as SRP-verified: TKPRPGP sequence; free acid vs amide termini; CAS; UNII; CID; salt/counter-ion (acetate vs TFA vs free base); a public COA file; a published laboratory dose.
Opened SRP index card (compound-research-guides, 16 August 2026): “Selank (10 mg Vial)” under Cognitive; tagged Evidence profile (not Dedicated evidence guide). Overview: Selank is a synthetic heptapeptide analogue related to the immunomodulatory peptide tuftsin and studied mainly in anxiety, cognition, and gene-expression research. That index sentence is vendor/index copy, not a treatment claim. Mechanism: proposed actions include modulation of neurotransmitter systems and immune-neural signaling, but no single mechanism fully explains the reported effects. Evidence: human reports exist, but the literature is geographically concentrated and often small. Large independent, internationally replicated trials are limited. Quality note: separate peer-reviewed findings from marketing claims and verify the full seven-amino-acid sequence. Last editorial review on that index: August 2026.
Opened dedicated-guide URL http://simpleresearchpeptides.com/research-compound-directory/selank-research/ returned HTTP 404. This page is written for that missing guide.
query.term=selank totalCount 10. Opened hits are lexical (balance exercises, PSAPs, a study ID containing TP7, brivaracetam). Unused as Selank-peptide evidence.Catalog “Brain & Mind / anxiety / cognition” language does not convert a research heptapeptide into tuftsin, Semax, or an approved anxiolytic. This page does not make anxiolytic treatment claims.
| Identity | What opened sources actually describe | Peptide? | Typical literature role |
|---|---|---|---|
| Selank (this page) | 7 aa; TKPRPGP; CID 11765600; CAS 129954-34-3; UNII TS9JR8EP1G; C33H57N11O9; 751.9 g/mol | Yes (heptapeptide, free-acid CID) | Tuftsin analog + C-terminal Pro-Gly-Pro. Preclinical serotonin / BDNF / enkephalinase literature. Small, regionally concentrated human reports. Not an approved drug. |
| Tuftsin | 4 aa; TKPR; H-Thr-Lys-Pro-Arg-OH; CID 156080; CAS 9063-57-4; UNII QF5336J16C; C21H40N8O6; 500.6 g/mol; InChIKey IESDGNYHXIOKRW-YXMSTPNBSA-N | Yes (tetrapeptide) | Endogenous spleen-derived phagocytosis-stimulating fragment of IgG. Not Selank. Semenova 2009 and Kozlovskaya 2003 distinguish the two. |
| Semax | 7 aa; MEHFPGP; CID 9811102; CAS 80714-61-0; UNII I5FAL2585H; ACTH(4-7)-Pro-Gly-Pro analog | Yes (different heptapeptide) | ACTH-fragment analog. BDNF / ischemia literature. Not Selank. Separate SRP 10 mg listing. |
| Pro-Gly-Pro tail alone | Shared C-terminal tripeptide of both Selank and Semax | Fragment, not the vial | Shared design motif. Does not make the two heptapeptides interchangeable. |
Selank is not tuftsin. Tuftsin is the tetrapeptide Thr-Lys-Pro-Arg (CID 156080). Selank appends Pro-Gly-Pro to that tuftsin core. Semenova et al. 2009 (PMID 19803361) printed both sequences and reported different effects on serotonin metabolism after PCPA pretreatment: Selank enhanced 5-HT metabolism in the brain stem; tuftsin did not, and decreased it in neocortex. Kozlovskaya et al. 2003 (PMID 14969422) compared Selank with short tuftsin-family peptides in rodent stress models. Do not cite tuftsin phagocytosis literature as Selank evidence.
Selank is not Semax. Semax is Met-Glu-His-Phe-Pro-Gly-Pro (CID 9811102), an ACTH(4-10) analog. The two share a C-terminal Pro-Gly-Pro and appear together in Kost et al. 2001 (PMID 11443939) as separate inhibitors of human-serum enkephalin-degrading enzymes (opened IC50: Semax 10 µM; Selank 20 µM). Shared enzyme-assay data are not identity.
Do not equate this vial with tuftsin, Semax, ACTH, melanotan, or an FDA-approved anxiolytic. Research use only.
Opened primary papers support a tuftsin-analog / glyproline working model with effects on enkephalin-degrading enzymes, monoamines, and hippocampal BDNF in rats / in-vitro serum. It is not a treatment claim. It was not generated with an SRP 10 mg vial. Observed means a measurement in an opened paper. Proposed means a hypothesis. Not shown means the opened papers did not establish it for a research-market lot.
Kost 2001 (PMID 11443939): Semax and Selank inhibited human-serum enkephalin-degrading enzymes. Opened abstract IC50: Semax 10 µM; Selank 20 µM. Zozulya 2001 (PMID 11550013): Selank IC50 15 µM vs plasma enkephalin hydrolysis. In vitro. Not a receptor assignment.
Semenova 2009 (PMID 19803361): in Wistar rats pretreated with PCPA, Selank enhanced 5-HT metabolism in the brain stem 30 min after injection. Tuftsin induced no brain-stem change and decreased 5-HT metabolism in neocortex. Direct chemical distinction.
Inozemtseva 2008 (PMID 18841804): intranasal Selank regulated BDNF expression in the rat hippocampus in vivo. Rat gene-expression finding. Not a human BDNF trial. Not an SRP-lot result.
Observed — tuftsin-family behavioral pharmacology (rodents). Kozlovskaya et al. 2003 (PMID 14969422): Selank and short tuftsin-family peptides affected behavioral manifestations of emotional stress in rats and inbred mice. Rodent conflict-situation work. Not a human RCT.
Historical human reports — not a treatment claim. Zozulia et al. 2008 (PMID 18454096): 62 patients with GAD and neurasthenia; Selank (n=30) compared with medazepam (n=32); psychometric scales plus serum enkephalin activity. Authors described similar anxiolytic effects plus antiasthenic / psychostimulant language for Selank. Uchakina et al. 2008 (PMID 18577961): immunomodulatory / Th1–Th2 cytokine observations in patients with anxiety-asthenic disorders and in vitro IL-6 effects. These are opened historical reports from a geographically concentrated literature. They are not FDA indications, not internationally replicated Phase 3 packages, and not evidence that an SRP 10 mg research vial treats anxiety. This page does not adopt those author sentences as treatment claims.
Not shown for an SRP 10 mg vial. Not shown on an opened page: a completed cell-surface receptor assignment; human PK of a research-market lot; proof that the SRP lot is CID 11765600 free acid rather than acetate or TFA salt; BDNF / enkephalinase data generated with that lot; a US ClinicalTrials.gov Selank-peptide administration record; FDA approval.
Label every row. Selank ≠ tuftsin ≠ Semax. Historical “anxiolytic” language is not a completed therapeutic program and is not an instruction.
Kost 2001 enkephalinase (PMID 11443939); Zozulya 2001 enkephalinase / proposed mechanism (PMID 11550013); Kozlovskaya 2003 tuftsin-family rodent behavior (PMID 14969422); Inozemtseva 2008 rat hippocampal BDNF (PMID 18841804); Semenova 2009 Selank vs tuftsin serotonin (PMID 19803361).
Zozulia 2008 GAD / neurasthenia comparison with medazepam (PMID 18454096). Uchakina 2008 cytokine / immunomodulatory observations (PMID 18577961). Geographically concentrated. Not an SRP-vial trial. Not a treatment claim.
query.term=selank totalCount 10. All opened records inspected in the API JSON are lexical (balance, PSAPs, TP7 study-ID fragment, unrelated drugs). Do not invent a Selank administration NCT.
NCATS: Approval Year Unknown. No opened NDA/ANDA/BLA for Selank. Not an FDA-approved anxiolytic. Vendor identity is not independently verified: SRP prints the name Selank, AKA TP-7, 10 mg, “COA available,” and research-use-only footers, but does not display sequence, CAS, UNII, termini, salt, or a public COA file.
Read the “what it did not show” column. Published study designs are historical facts from those papers. They are not a protocol. Cell-culture micromolar concentrations and rodent schedules are study conditions, not instructions for an SRP 10 mg research vial.
| Study | Species / model | What was tested | Actual finding (from the opened record) | What it did not show |
|---|---|---|---|---|
| Kost et al., 2001 PMID 11443939. DOI 10.1023/a:1011373002885. Opened Europe PMC abstract. | Human serum enzymes, in vitro | Semax and Selank vs enkephalin-degrading enzymes | Dose-dependent inhibition. IC50 Semax 10 µM; Selank 20 µM. Heptapeptides and some pentapeptide fragments active. | Human RCT. Receptor assignment. SRP-vial identity. Semax = Selank. |
| Zozulya et al., 2001 PMID 11550013. DOI 10.1023/a:1017979514274. Opened Europe PMC abstract. | Human plasma; patients with anxiety/phobic disorders (enzyme half-life observations) | Selank vs plasma enkephalin hydrolysis | IC50 15 µM. Authors propose enkephalinase inhibition as a possible anxiolytic mechanism. Shortened enkephalin half-life observed in GAD (not panic/agoraphobia) in that paper. | FDA indication. SRP lot. Completed receptor. A protocol. This page does not adopt the 2001 hypothesis as a treatment claim. |
| Kozlovskaya et al., 2003 PMID 14969422. DOI 10.1023/a:1025988519919. Opened Europe PMC abstract. | Rats; C57BL/6 and Balb/c mice; Wistar rats | Selank and tuftsin-family short peptides in conflict / stress models | Positive emotional / antistress actions in those models; individual peptide-structure effects. | Human efficacy. Tuftsin equivalence. |
| Inozemtseva et al., 2008 PMID 18841804. DOI 10.1134/s0012496608040066. Opened Europe PMC record. | Rat hippocampus, in vivo | Intranasal Selank | Regulated BDNF expression. Rats. | Human BDNF trial. SRP lot. Treatment claim. |
| Semenova et al., 2009 PMID 19803361. Opened Europe PMC abstract. | Wistar rats, PCPA-pretreated | Selank vs tuftsin on 5-HT metabolism | Selank enhanced brain-stem 5-HT metabolism at 30 min; tuftsin did not (neocortex decrease). Sequences printed: Selank TKPRPGP; tuftsin TKPR. | Human serotonin trial. Identity collapse. |
| Zozulia et al., 2008 PMID 18454096. Opened Europe PMC abstract. | 62 patients, GAD / neurasthenia | Selank (n=30) vs medazepam (n=32) | Authors: similar anxiolytic effects; Selank also described as antiasthenic / psychostimulant; leu-enkephalin t½ correlations. Historical comparative report. | FDA approval. International Phase 3. Equivalence of an SRP vial. A dosing protocol. Not a treatment claim on this page. |
| Uchakina et al., 2008 PMID 18577961. Opened Europe PMC abstract. | Patients with anxiety-asthenic disorders; in vitro PBMC | Selank | In vitro IL-6 gene-expression suppression at 10−7 M in patient (not control) blood; in vivo Th1/Th2 cytokine-balance changes over 14 days. Historical immunomodulatory report. | FDA indication. SRP lot. Infectious-disease prevention claim. |
Human / NCT snapshot. No opened Selank-peptide administration NCT on ClinicalTrials.gov. Do not invent one. Do not treat lexical hits as drug trials.
These are gaps. Treating any of them as settled is incorrect.
NCATS approval year: Unknown. No opened NDA. Not an FDA-approved anxiolytic.
CT.gov selank hits are lexical. Do not invent an administration NCT.
Sequence, termini, CAS, UNII, salt, and a public COA were not printed on the SRP page.
Not shown for an SRP lot and not an approved mechanism of action.
Inozemtseva 2008 and Semenova 2009 are rodent papers. They are not a human anxiolytic indication.
Different sequences. Different parents. Shared Pro-Gly-Pro is a motif, not identity.
Not internationally replicated. Not a reason to treat or dose a research vial. Not a treatment claim.
No opened bioavailability, chronic toxicology, carcinogenicity, or reproductive-tox package.
| Popular claim | Status after this review |
|---|---|
| “Selank is an FDA-approved anxiolytic” | False on the opened record. |
| “It is tuftsin in a 7-aa vial” | False identity. Tuftsin is TKPR (CID 156080). Selank is TKPRPGP. Semenova 2009 shows different 5-HT effects. |
| “It is Semax” | False. Different sequence (MEHFPGP vs TKPRPGP); different parent (ACTH vs tuftsin). |
| “Enkephalinase IC50 proves a human anxiety indication” | Unsupported. In-vitro serum assay + 2001 hypothesis. Not a treatment claim. |
| “The SRP 10 mg vial is the Zozulia 2008 / Inozemtseva 2008 lot” | Not established. Sequence and salt not printed. |
| “CT.gov lists Selank trials” | False for the peptide. Opened hits are lexical. |
| “This page is a treatment or dosing guide” | False. Research use only. No protocol. |
Each card is a single opened record. Historical human language is not a protocol. Micromolar IC50 values and rodent schedules are study conditions, not instructions.
Semax and Selank inhibit human-serum enkephalin-degrading enzymes. IC50 10 µM (Semax) and 20 µM (Selank) in that assay. In vitro. Distinguishes the two heptapeptides while showing a shared enzyme class. PMID 11443939.
Selank IC50 15 µM vs plasma enkephalin hydrolysis. Authors propose this as a possible anxiolytic mechanism. Hypothesis, not approval. Not a treatment claim on this page. PMID 11550013.
Selank and tuftsin-family short peptides in rodent stress / conflict models. Selank ≠ tuftsin fragments. PMID 14969422.
Intranasal Selank regulated BDNF expression in rat hippocampus. Rats. PMID 18841804.
Selank vs tuftsin on 5-HT metabolism after PCPA. Different effects. Sequences printed. PMID 19803361.
Historical GAD / neurasthenia comparison with medazepam (n=62). Not FDA evidence. Not a protocol. Not a treatment claim. PMID 18454096.
Historical cytokine / immunomodulatory observations. Not an infectious-disease indication. PMID 18577961.
Selank is an investigational laboratory research heptapeptide. It is not an FDA-approved drug for human use. This page is educational. It does not provide dosing, reconstitution, administration, or any human-use instructions. The 10 mg mass is a vendor listing, not a published laboratory protocol.
Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application.
Laboratory identity is the first practical issue. Opened registries describe Selank as CID 11765600 / CAS 129954-34-3 / UNII TS9JR8EP1G / H-TKPRPGP-OH. SRP product pages do not print sequence, CAS, UNII, termini, salt, or a public COA. A method written for tuftsin, Semax, ACTH, or an approved anxiolytic is not automatically valid for this vial.
Confirm peptide identity, termini (free acid vs amide), stereochemistry, salt, and purity by LC-MS before treating a vial as the literature article. Independently sourced research peptides are not established as equivalent to Inozemtseva 2008 or Zozulia 2008 material. Historical rodent schedules and micromolar enzyme IC50 values are study conditions from those papers. They are not a reconstitution scheme.
No reconstitution scheme, no administration route, and no human or veterinary use protocol appears on this page. Research use only.
No. Tuftsin is the tetrapeptide Thr-Lys-Pro-Arg (CID 156080; CAS 9063-57-4; UNII QF5336J16C). Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro. Semenova 2009 printed both sequences and reported different serotonin-metabolism effects.
No. Semax is Met-Glu-His-Phe-Pro-Gly-Pro (CID 9811102), an ACTH(4-10) analog. They share a C-terminal Pro-Gly-Pro and appear as separate compounds in Kost 2001.
TP-7 is a depositor / marketplace synonym on CID 11765600. It is not a second verified peptide. Confirm sequence on a COA.
That is the Kost 2001 / Zozulya 2001 in-vitro working model. It is not a completed receptor assignment and not an approved mechanism.
Inozemtseva 2008 reported BDNF regulation in rat hippocampus after intranasal Selank. That is not a human BDNF trial and not an SRP-lot result.
No. NCATS approval year: Unknown. This page does not make treatment claims.
No opened Selank-peptide administration NCT. CT.gov selank hits are lexical collisions.
Not established. Sequence, termini, and salt are not printed. Confirm on a COA / LC-MS.
No. SRP listings are for laboratory research only and are not for human or animal use. This page does not provide reconstitution, administration, or dosing instructions.
No. There is no human dosing, reconstitution, or administration protocol on this page. Research use only. Not medical advice. Not for human use.
Sources actually opened for this draft. Do not add PMIDs or NCTs that are not on the allowed list.
query.term=selank (totalCount 10), opened 16 August 2026. Lexical / unused: NCT06151093, NCT05076045, NCT01770990, others. No Selank-peptide administration NCT used.Allowed PMID list used on this page: 11443939, 11550013, 14969422, 18841804, 19803361, 18454096, 18577961. No administration NCT.
Educational information only. The SRP listing Selank 10 mg is a research peptide corresponding, on opened registries, to Selank / TKPRPGP (CID 11765600; CAS 129954-34-3; UNII TS9JR8EP1G; H-TKPRPGP-OH; C33H57N11O9; 751.9 g/mol). It is not tuftsin, not Semax, and not an FDA-approved anxiolytic. No opened Selank-peptide NCT. Not FDA-approved. Termini and salt of an SRP lot are not printed. Historical rodent schedules, micromolar IC50 values, and 2008 comparative reports are study conditions / historical literature, not instructions. This page does not make anxiolytic treatment claims. Laboratory research use only; not for human or animal use. Not medical advice. Not for human use. No human dosing protocol. Last source review: 16 August 2026 (America/Indianapolis). For laboratory research only. Not for human or veterinary use.
| Identifier | Value on opened page | Source opened |
|---|---|---|
| Peptide sequence | TKPRPGP; IUPAC condensed H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH; PLN H-TKPRPGP-OH; HELM PEPTIDE1{T.K.P.R.P.G.P}; IUPAC L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolyl-glycyl-L-proline | CID 11765600 biologic description |
| PubChem title | Selank | PubChem HTML, opened 16 August 2026 |
| PubChem CID | 11765600 (7 defined / 0 undefined stereocenters) | PubChem HTML + PUG REST |
| CAS | 129954-34-3 | PubChem CID 11765600 HTML (ChemIDplus; EPA DSSTox); NCATS UNII page |
| UNII | TS9JR8EP1G | PubChem synonym block; TS9JR8EP1G title SELANK; Approval Year Unknown |
| Formula / MW | C33H57N11O9; 751.9 g/mol | PubChem HTML + PUG |
| Exact / monoisotopic mass | 751.43407244 Da | PubChem PUG |
| InChIKey | JTDTXGMXNXBGBZ-YVHUGQOKSA-N | PubChem HTML + PUG |
| EPA DSSTox | DTXSID701029276 | PubChem; NCATS |
| RxCUI | 2049928 | NCATS |
| MeSH | Selank (M0408941) | PubChem MeSH |
| Depositor synonyms (selected) | Selanc; Thr-Lys-Pro-Arg-Pro-Gly-Pro; TP-7; TP 7; TP-7 (diacetate); UNII-TS9JR8EP1G; HY-105042 | PubChem synonym block. Diacetate alias is a depositor string, not proof of the SRP lot salt |
| NCATS Inxight | SELANK; Other; Approval Year Unknown; sequence THR-LYS-PRO-ARG-PRO-GLY-PRO | TS9JR8EP1G |
| ClinicalTrials.gov | query.term=selank: totalCount 10. Opened hits are lexical. No opened Selank-peptide administration NCT. | CT.gov API v2, opened 16 August 2026 |
| FDA-approved Selank drug | None on opened PubChem / NCATS / CT.gov pages. NCATS approval year: Unknown | Same |
| SRP listing | 10 mg vial ($25.00); Brain & Mind Research; AKA TP-7 | SRP product page |
Registry chaos that must not be collapsed. PubChem diacetate synonym is alias noise on the free-acid CID. ClinicalTrials.gov selank hits include NCT06151093 (balance exercises), NCT05076045 (personal sound amplification products / PSAPs), NCT01770990 (telephone psychotherapy; org ID contains TP7), and other lexical collisions. Unused as Selank-peptide evidence. TP-7 is a depositor / marketplace synonym on CID 11765600. It is not a second verified peptide. Tuftsin (CID 156080; TKPR) is the parent tetrapeptide, not Selank.
One-sentence identity restated: Selank (also Selanc / TP-7) is a synthetic heptapeptide tuftsin analog with opened sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro / TKPRPGP (CID 11765600; CAS 129954-34-3; UNII TS9JR8EP1G; formula C33H57N11O9; MW 751.9 g/mol). It is not tuftsin, not Semax, and not an FDA-approved anxiolytic. Opened human reports are geographically concentrated and small. Human efficacy of a research-market 10 mg vial is not established. This page does not make anxiolytic treatment claims.
Kost PMID 11443939 and Zozulya PMID 11550013 report in-vitro inhibition of human-serum / plasma enkephalin-degrading enzymes. IC50 values in those assays are study conditions. The 2001 “possible anxiolytic mechanism” sentence is a hypothesis, not an approval and not a protocol.
PMID 14969422: Selank and short tuftsin-family peptides in rodent stress / conflict models. Selank is not interchangeable with tuftsin fragments.
Inozemtseva PMID 18841804 (rat hippocampal BDNF). Zozulia PMID 18454096 and Uchakina PMID 18577961 are geographically concentrated historical reports. Not FDA evidence. Not a treatment claim. Not a protocol.
PMID 19803361 printed both sequences and reported different serotonin-metabolism effects after PCPA. Direct chemical distinction.
Product page prints name, 10 mg, AKA TP-7, $25.00, RUO footer. Sequence, CAS, UNII, termini, salt, and a public COA were not printed. Index tags Evidence profile. Dedicated selank-research URL returned HTTP 404. CT.gov selank hits are lexical. No administration NCT.
Reference identifiers used in this guide. PubMed IDs: 11443939, 11550013, 14969422, 18841804, 19803361, 18454096, 18577961. Distinction-only CIDs: 156080 (tuftsin), 9811102 (Semax).
2 mins ago